The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of VERB, KPTI and CURLF
NEW YORK, NY / ACCESSWIRE / August 21, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.
Verb Technology Company, Inc. (f/k/a nFüsz, Inc.) (VERB)
Class Period: January 3, 2018 to May 2, 2018
Lead Plaintiff Deadline: September 9, 2019
The filed complaint alleges that Verb Technology Company, Inc. (f/k/a nFüsz, Inc.) violated federal securities laws by issuing materially false and/or misleading information and/or failing to disclose material information. Specifically, Defendants made false and/or misleading statements as to the scope of the Agreement with Oracle as the Company did not have a contract with Oracle to jointly develop and market the Company’s product and that as a result of the foregoing, the Company’s public statements were materially false and misleading at all relevant times.
Learn about your recoverable losses in VERB: http://www.kleinstocklaw.com/pslra-1/verb-technology-company-inc-f-k-a-nfusz-inc-fusz-loss-submission-form?id=3098&from=1
Karyopharm Therapeutics Inc (KPTI)
Class Period: on behalf of shareholders of Karyopharm Therapeutics Inc. who: (1) purchased shares of Karyopharm’s common stock between March 2, 2017 and February 22, 2019, inclusive; (2) purchased Karyopharm shares in or traceable to the Company’s public offering of common stock conducted on or around April 28, 2017; or (3) purchased Karyopharm shares in or traceable to the Company’s public offering of common stock conducted on or around May 7, 2018.
Lead Plaintiff Deadline: September 23, 2019
The lawsuit alleges Karyopharm Therapeutics Inc made materially false and/or misleading statements and/or failed to disclose during the class period that: Throughout the Class Period, the Company continued to tout the commercial prospects for selinexor and consistently described selinexor as having a “predictable and manageable tolerability profile” and a “very nice safety profile,” and assured investors that it was “well tolerated” by patients. Karyopharm also claimed that selinexor had the potential to be used as a new treatment for MM, with limited and manageable side effects. As a result of these misrepresentations, Karyopharm shares traded at artificially inflated prices during the Class Period.
Learn about your recoverable losses in KPTI: http://www.kleinstocklaw.com/pslra-1/karyopharm-therapeutics-inc-loss-submission-form?id=3098&from=1
Curaleaf Holdings, Inc. (CURLF)
Class Period: November 21, 2018 to July 22, 2019
Lead Plaintiff Deadline: October 4, 2019
The complaint alleges Curaleaf Holdings, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Curaleaf, on its website and social media pages, marketed its CBD products to be used as drugs and dietary supplements, contrary to law; (2) Curaleaf also sold unapproved animal drugs on its website; (3) such conduct would result in a warning letter from the U.S. Food and Drug Administration; and (4) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
Learn about your recoverable losses in CURLF: http://www.kleinstocklaw.com/pslra-1/curaleaf-holdings-inc-loss-submission-form?id=3098&from=1
Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com
SOURCE: The Klein Law Firm
View source version on accesswire.com:
https://www.accesswire.com/556915/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-VERB-KPTI-and-CURLF
